Sinovac Biotech Ltd
F:SVQ

Watchlist Manager
Sinovac Biotech Ltd Logo
Sinovac Biotech Ltd
F:SVQ
Watchlist
Price: 5.58 EUR Market Closed
Market Cap: 556m EUR

Gross Margin
Sinovac Biotech Ltd

92.1%
Current
63%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
92.1%
=
Gross Profit
395.3m
/
Revenue
429.2m

Gross Margin Across Competitors

No Stocks Found

Sinovac Biotech Ltd
Glance View

Market Cap
556m EUR
Industry
Biotechnology

Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company is headquartered in Beijing, Beijing and currently employs 1,959 full-time employees. The company went IPO on 2009-11-13. The firm is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The firm's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The firm is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The firm develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

SVQ Intrinsic Value
HIDDEN
Show
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
92.1%
=
Gross Profit
395.3m
/
Revenue
429.2m
What is the Gross Margin of Sinovac Biotech Ltd?

Based on Sinovac Biotech Ltd's most recent financial statements, the company has Gross Margin of 92.1%.

Back to Top